Nipocalimab's Unique Mechanism Gets Second Chance in RA

The trial proved that nipocalimab reduced IgG antibodies, including anti-citrullinated protein autoantibodies, but the primary endpoint was missed.
Medscape Medical News

source https://www.medscape.com/viewarticle/nipocalimabs-unique-mechanism-gets-second-chance-rheumatoid-2024a100091h?src=rss

Comments

Popular posts from this blog

RA and RA-ILD Linked to Higher Lung Cancer Risk

DC’s Harllee Harper Is Using Public Health Tools to Prevent Gun Violence. Will It Work?